Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700617 | 0.85 | ADRA2A (0.41) | TAAR1 | |
| SCHEMBL19812300 | 0.85 | TAAR1 (0.37) | TAAR1HRH1 | |
| SCHEMBL13442239 | 0.84 | TAAR1 (0.42) | TAAR1HRH1HTR2A | |
| SCHEMBL7438547 | 0.83 | NPSR1 (0.36) | TAAR1 | |
| SCHEMBL16113242 | 0.82 | TAAR1 (0.35) | TAAR1 | |
| SCHEMBL19812305 | 0.82 | L3MBTL1 (0.40) | TAAR1 | |
| SCHEMBL2325955 | 0.81 | RIPK1 (0.36) | TAAR1 | |
| SCHEMBL7240943 | 0.81 | RIPK1 (0.36) | TAAR1 | |
| SCHEMBL9853837 | 0.81 | L3MBTL1 (0.44) | — | |
| SCHEMBL15283292 | 0.81 | RIPK1 (0.36) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | TAAR1 195/4885HRH1 687/4885HTR2A 642/4885 |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | TAAR1 336/4885HRH1 679/4885HTR2A 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.